Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $10.14 Consensus Target Price from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $10.14.

Several analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. HC Wainwright reduced their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, March 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Finally, Bank of America reduced their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th.

Neumora Therapeutics Stock Down 2.6 %

Shares of NASDAQ:NMRA opened at $1.13 on Tuesday. The company has a market cap of $183.04 million, a price-to-earnings ratio of -0.60 and a beta of 2.59. The firm’s 50-day simple moving average is $1.72 and its 200-day simple moving average is $7.90. Neumora Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NMRA. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics during the fourth quarter worth about $61,000. PNC Financial Services Group Inc. acquired a new position in Neumora Therapeutics during the fourth quarter worth about $64,000. Quantbot Technologies LP acquired a new position in Neumora Therapeutics during the fourth quarter worth about $92,000. PEAK6 LLC acquired a new position in Neumora Therapeutics during the fourth quarter worth about $117,000. Finally, EntryPoint Capital LLC acquired a new position in Neumora Therapeutics during the fourth quarter worth about $135,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.